TICKERNERD
Menu
BCAXBCAXHealthcare · Biotechnology

BCAX Stock Forecast: Bicara Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$18
−1.68% on the day

The 14 Wall Street analysts covering Bicara Therapeutics, Inc. hold a median 12-month price target of $36 — +101.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 21 Oct 2026 — in the upper half.

Market cap
$1.2B
Ticker Nerd rank
52/ 100
Median analyst target
$36
Analysts covering
14
Revenue$0.0
Operating income−$60.0M
Net income−$55.4M
Free cash flow−$44.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.1%
1M
−22.7%
YTD
+4.6%
1Y
+7.1%
From 52W high
−42.1%
From 52W low
+26.4%
$14
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bicara Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
52/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
86
Value
72
Revisions
60
Quality
59
Accruals
49
Size
42
Volatility
41
Issuance
32
Growth
24

Momentum (86): The shares have been drifting up relative to others.

Growth (24): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26BCAXHigh $45Median $36Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $20Median $36High $45

The green dot is the last close — the median target sits +101.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Oct 2026BTIGReiteratesBuy$39
19 Aug 2026BMO CapitalInitiatesOutperform$35
12 Aug 2026BTIGMaintainsBuy$28 → $39
12 Aug 2026Goldman SachsMaintainsNeutral$18 → $20
12 Aug 2026MizuhoMaintainsNeutral$18 → $20
12 Aug 2026Morgan StanleyMaintainsOverweight$37 → $39
12 Aug 2026WedbushMaintainsOutperform$30 → $33
12 Aug 2026Wells FargoMaintainsEqual-Weight$16 → $23
12 May 2026Goldman SachsMaintainsNeutral—
12 May 2026Goldman SachsMaintainsNeutral$16 → $18
12 May 2026Morgan StanleyMaintainsOverweight—
12 May 2026Morgan StanleyMaintainsOverweight$36 → $37
11 May 2026GuggenheimInitiatesBuy$42
11 May 2026GuggenheimInitiatesBuy—
31 Mar 2026CitizensReiteratesMarket Outperform—
31 Mar 2026Goldman SachsMaintainsNeutral—
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushReiteratesOutperform—
31 Mar 2026Wells FargoMaintainsEqual-Weight—
25 Mar 2026B of A SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

BCAX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

BCAX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Bicara Therapeutics, Inc. returned +7.1% against +15.6% for the S&P 500, dividends included.

BCAX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26BCAXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BCAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
8
Analysts cutting
3
Fundamentals

Bicara Therapeutics, Inc. (BCAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.4×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
−3.6×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−41.0%

Higher than 24% of US stocks

Return on assets
−26.1%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Bicara Therapeutics, Inc. (BCAX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bicara Therapeutics, Inc. has a market value of $1.2B and an enterprise value of $718.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$185.4M.

  • Diluted earnings per share, trailing twelve months: $−3.10.

  • Free cash flow in the twelve months to 30 June 2026: −$135.2M.

  • Shares outstanding: 65.5M.

  • Trailing P/E: 3.4×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Bicara Therapeutics, Inc. employs 103 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Oct 2026

Data provided by Twelve Data

Peers

BCAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BCAXBicara Therapeutics, Inc.$1.2B52
OMEROmeros Corp.$1.2B92
IMTXImmatics NV$1.2B40
KARDKardigan, Inc.$1.2B0
RAPPRapport Therapeutics, Inc.$1.2B47
SNDXSyndax Pharmaceuticals, Inc.$1.1B57
VORVor Biopharma, Inc.$1.1B21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Bicara Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCAX news & analysis

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 5 Oct 2026neutral

Bicara Therapeutics announced that on October 1, 2026, it awarded inducement grants to two new employees as a material inducement to employment under its 2026 Inducement Plan. The company is a clinical-stage biopharmaceutical firm focused on bifunctional therapies for solid tumors.

Why it matters — This regulatory disclosure, required under Nasdaq Listing Rule 5635(c)(4), informs BCAX watchers about equity awards issued in connection with new hires.

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Sept 2026neutral

Bicara Therapeutics announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under its 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of the company's standard practice for attracting new hires.

Why it matters — BCAX watchers would care because the new-hire inducement grants are routine equity compensation activity that signals continued hiring and company growth without indicating changes to its business outlook.

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 14 Aug 2026neutral

Bicara Therapeutics announced that, effective August 12, 2026, it awarded an inducement grant to Jennifer Larson under its 2026 Inducement Plan as a material inducement to her commencement of employment as Chief Financial Officer. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, equal to the Nasdaq closing price on August 12, 2026.

Why it matters — A BCAX watcher would care because it confirms the appointment of Jennifer Larson as the company's new Chief Financial Officer along with the associated equity-based inducement grant.

Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds

Seeking Alpha · 12 Aug 2026positive

A Seeking Alpha article upgraded Bicara Therapeutics to 'Buy', citing favorable early clinical signals for ficerafusp alfa in head and neck cancer, though it noted that toxicity and small cohort size warrant caution ahead of the pivotal phase 3 readout.

Why it matters — BCAX watchers would care because the article highlights encouraging phase 1 data for the company's lead candidate and a strong cash runway into 2029, while also pointing to the upcoming phase 3 results as a key catalyst to monitor.

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Benzinga · 12 Aug 2026positive

Bicara Therapeutics (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter. Following the results, analysts raised their forecasts for the company.

Why it matters — A narrower-than-expected quarterly loss and upward analyst revisions signal improved sentiment around Bicara's financial performance for investors tracking the stock.

FAQ

Frequently asked questions about BCAX stock

What is the BCAX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Bicara Therapeutics, Inc. have a median 12-month price target of $36, with estimates ranging from $20 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCAX stock a buy right now?

Of the 14 analysts covering Bicara Therapeutics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bicara Therapeutics, Inc. 52 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCAX?

As at 21 Oct 2026, Bicara Therapeutics, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).

Will BCAX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +101.6% from the last close, and Ticker Nerd's factor model ranks Bicara Therapeutics, Inc. 52 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCAX stock forecast for 2030?

No analyst covering Bicara Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $45 over the next 12 months.

How has BCAX stock performed over the past year?

Bicara Therapeutics, Inc. returned +7.1% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bicara Therapeutics, Inc. do?

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.

What is the latest news on BCAX?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)". Bicara Therapeutics announced that on October 1, 2026, it awarded inducement grants to two new employees as a material inducement to employment under its 2026 Inducement Plan. The company is a clinical-stage biopharmaceutical firm focused on bifunctional therapies for solid tumors.

Company

About Bicara Therapeutics, Inc.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, is designed to combine EGFR targeting with TGF-β modulation, aiming to concentrate activity within the tumor microenvironment while limiting broader systemic effects. The company’s platform is built around dual-action biologics intended to pair precise tumor targeting with localized immune and signaling modulation. Bicara Therapeutics Inc. is centered on oncology, with current development efforts directed toward multiple solid tumor indications, including head and neck squamous cell carcinoma. Through this approach, the company plays a role in advancing next-generation cancer biologics that seek to address difficult-to-treat tumors using a more integrated therapeutic design.

CEO Dr. Claire Mazumdar Clemon M.B.A., Ph.D. · 103 employees · United States · https://www.bicara.com